
Guard Therapeutics Intl Investor Relations Material
Latest events

R&D Update
Guard Therapeutics Intl

Q2 2025
21 Aug, 2025

Q1 2025
5 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Guard Therapeutics Intl
Access all reports
Guard Therapeutics International AB is a Swedish biopharmaceutical company focused on the development of therapies for the diagnosis and treatment of acute kidney injuries. The company is most known for its investigational drug, ROSGard, a biological candidate designed to prevent kidney damage by mimicking the body's defense system against oxidative stress, thereby protecting, cleaning, and repairing exposed cells and tissues. Guard Therapeutics is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq First North.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
GUARD
Country
🇸🇪 Sweden